Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Head of Bayer LifeScience Center: Expect More JVs

This article was originally published in Scrip

Executive Summary

The head of Bayer AG's new "breakthrough" R&D unit expects to form more joint ventures with cutting-edge biotechnology start-ups like the one announced with Switzerland-based CRISPR Therapeutics aimed at harnessing their technologies and linking them with Bayer's expertise.


Related Content

Bayer/Versant Launch New Stem Cell Company With Massive Cash Injection
Scrip's Rough Guide To CRISPR Gene Editing





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst